Some of the illnesses and prescriptions are treated differently as a result of the ethnicity of people. The healthcare providers have to be aware of the connection of the disease with the cultural practices of the various races. Many people suffer from the MDD despite their race, sex, and age. The medical professionals should examine and handle individuals with MDD. According to the APA (2013), a patient should have more than five signs contained in the DSM-5 to be diagnosed with MDD. The medical symptoms have to be experienced in two weeks which include moodiness and reduced concern in personal tasks. The main signs of MDD are insomnia, loss of appetite along with weight (APA, 2013). The case focuses on a Hispanic man who lives in America after emigrating from Mexico. The man is suffering from depression and low interest in his private activities. The patient has lost weight in the past eight weeks. He has insomnia in the past 24 weeks and has lost concentration. Concerning the results of the mental health, the patient is attentive and bears *3. The results of the MADRS indicated that the patient scored 51.
Decision 1
I decided to administer 25 milligrams of Sertraline to the patient by mouth. The option focuses on the medical symptoms portrayed by the client including insomnia and mood swings. The other sign is self-confidence (Stahl, 2013). Sertraline will assist the patient to improve the signs of the atypical stress that has resulted in increasing his weight by 15 kg (Stahl, 2013). The outcome of the option indicated that the patient reduced the signs of the condition by 25 %. The presumed response was below than the met results. The immediate situation of erectile dysfunction occurred due to the limited time of the prescription and low quantity of Sertraline. The strategy was to start with an order of 25 milligrams per day to 50 to 200 milligrams in a day (Laureate Education, 2016g).
Delegate your assignment to our experts and they will do the rest.
Decision #2
The plan was to continuously administer the similar dosage and provide counseling to the client. The purpose of making the decision is because the prescription had a response rate of 25 %. The medication had effects of erectile dysfunction which can discourage the patient from taking. The dosage cannot be changed because the symptoms can increase which will prompt the client from declining the treatment (Stahl, 2013). The option aims to assist the client use the drugs in spite of the consequences. Stahl (2013), claimed that one of the effects of Sertraline is erectile dysfunction. The patient should use the medication because the symptoms occur for a short time (Laureate Education, 2016g). The expectations did match with the met outcome. The patient had stopped taking the medication due to its effects on low sexual performance (Laureate Education, 2016g). The healthcare provider can reduce the dosage to 12.5 milligrams in a day which can lead to a relapse.
Decision 3
The solution was to motivate the patient to use the previous dosage (Laureate Education, 2016g). The recommended quantity of Sertraline is 50 milligrams in a day (Stahl, 2013). The presumption was to get a reduction of 25 % of the symptoms. Sertraline reduces the condition of the client (Stahl, 2013). The aim is to achieve a maximum response from the medication. In case the prescription increases the negative signs, the class of medicine will be changed. The recommendation is that it should to Bupropion taking into account that the SSRI should be tested before changing the drug levels.
Ethical Considerations
The client grew up in America, but various races manage stress in their methods. The healthcare provider should be culturally sensitive concerning the patient's race. Beeker, Schlaepfer & Coenen (2017), claimed that healthcare providers should take into account the patient’s propensity to formulate decisions on their health particularly on changing the treatment. The client’s independence should be upheld to implement the choices they have made (Beeker, Schlaepfer, & Coenen, 2017).
References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.
Beeker, T., Schlaepfer, T. E., & Coenen, V. A. (2017). Autonomy in depressive patients undergoing DBS-treatment: informed consent, freedom of will and DBS’ potential to restore it. Frontiers in Integrative Neuroscience , 11, 11. http://doi.org/10.3389/fnint.2017.00011
Laureate Education. (2016g). Case Study: An Elderly Hispanic Man with Major Depressive Disorder. [Interactive media file]. Baltimore, MD: Author.
Montgomery, S. A., & Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
Stahl, S. M. (2013). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). New York, NY: Cambridge University Press.
